Literature DB >> 29129261

Idarucizumab since FDA approval: Use in the real-world.

Joseph Ebinger1, Christopher B Granger2, Alexander Zhu3, Allison Chang1, Timothy D Henry4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29129261     DOI： 10.1016/j.ahj.2017.08.007

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  3 in total

1.  Assessment of patients post reversal with idarucizumab.

Authors:  Veronica Raco; Tania Ahuja; David Green
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

2.  Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals.

Authors:  Jameel Abdulrehman; Sahar Zarabi; Carolyne Elbaz; Kerstin de Wit; Yulia Lin; Michelle Sholzberg; Rita Selby
Journal:  Res Pract Thromb Haemost       Date:  2021-08-07

Review 3.  Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal.

Authors:  Marco Proietti; Giuseppe Boriani
Journal:  Ther Clin Risk Manag       Date:  2018-08-22       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.